Holen Sie sich die Stockscreener-App
2.755
1.88%
0.045
Schlusskurs vom Vortag:
$2.71
Offen:
$2.67
24-Stunden-Volumen:
156.01K
Relative Volume:
0.27
Marktkapitalisierung:
$287.34M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-8.1029
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
-0.68%
1M Leistung:
-17.34%
6M Leistung:
-26.18%
1J Leistung:
-32.82%
1-Tages-Spanne:
$2.63
$2.785
1-Wochen-Bereich:
$2.62
$2.90
52-Wochen-Spanne:
$2.62
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.755 | 287.34M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
131.69 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.75 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
374.75 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.62 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.08 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte Expands Capital with New Stock Issuance - TipRanks
MaxCyte stock plunges to 52-week low, touches $2.75 - Investing.com
MaxCyte CFO completes RSU vesting and tax-related sale By Investing.com - Investing.com Australia
MaxCyte CFO completes RSU vesting and tax-related sale - Investing.com India
MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
MaxCyte executives receive equity incentives By Investing.com - Investing.com South Africa
MaxCyte executives receive equity incentives - Investing.com India
MaxCyte Awards Stock Options and Units to Executives - TipRanks
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock - Investing.com India
Maxcyte general counsel David Sandoval sells $1,122 in stock - Investing.com
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock - Investing.com
BlackRock Increases Stake in MaxCyte to 7.71% - TipRanks
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha
What is William Blair’s Estimate for MaxCyte Q1 Earnings? - Defense World
US Bancorp DE Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - Defense World
MaxCyte files annual report with SEC By Investing.com - Investing.com Australia
MaxCyte core business revenue grows despite overall decline By Investing.com - Investing.com Australia
Stifel cuts MaxCyte stock price target to $9 from $11 By Investing.com - Investing.com Australia
Stifel cuts MaxCyte stock price target to $9 from $11 - Investing.com
MaxCyte stock touches 52-week low at $3.11 amid market challenges By Investing.com - Investing.com South Africa
MaxCyte stock touches 52-week low at $3.11 amid market challenges - Investing.com Australia
MaxCyte’s Promising Financial Outlook and Strategic Growth Justify Buy Rating - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript - Insider Monkey
MaxCyte price target lowered to $6 from $8 at BTIG - TipRanks
MaxCyte stock price target cut to $6 at BTIG By Investing.com - Investing.com South Africa
MaxCyte price target lowered to $9 from $11 at Stifel - TipRanks
MaxCyte stock price target cut to $6 at BTIG - Investing.com India
MaxCyte files annual report with SEC - Investing.com India
MaxCyte core business revenue grows despite overall decline - Investing.com India
Maxcyte Sees 2025 Core Revenue To Grow 8% To 15% - Marketscreener.com
MaxCyte reports a return to core revenue growth in FY24 - DirectorsTalk Interviews
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates By Investing.com - Investing.com Australia
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte’s Strategic Expansion and Financial Resilience Drive Buy Rating - TipRanks
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates - Investing.com India
MaxCyte reports Q4 EPS (10c), consensus (12c) - TipRanks
MAXCYTE, INC. SEC 10-K Report - TradingView
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.80%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):